Rgshredder, for starters Przybyl figured that we should have been trading in Small Cap territory especially when they see that:
-ANIP is debt free,
-Has an abundance of manufacturing capacity for future growth (no dilution to expand operations),
- The pipeline and the Gross Margin (65.5%) on the products they produce (22% higher then Akorn, the closest competitor).
- Testosterone royalties by Teva around the corner.
Small cap puts PPS in excess of $30. So he will not be selling nor will any of his group. Besides there is no point in asking a question he can't answer without telling everyone.
One problem, as Homeslice pointed out, is there has been no coverage or marketing of the company since the merger. This conference is a first step. I believe a number of investors will see a place for ANIP in there portfolio once they understand the low cost business model and the pipeline setup will well above average returns.
Some stocks such as Stereotaxis have done well as a result of this conference, in 2012 they went from $1.37 on December 10th to $3.27 on January 2nd. A similar run would put ANIP in Small Cap territory.
Look at Lannett Pharma last December they were trading in the $5 with limited coverage. Increasing profits and increased coverage has elevated them to over $31. Increasing profits fueled by Tesneo and increased coverage could easily give us a similar continuous rise throughout next year.
Przybyl stated that he wanted to get one year of financial results as ANIP under his belt before actively doing a series of presentations. since some investors want some sort of a track record 4 quarters of continuous growth clear of BPAX would help. Interestingly that may also be about the time the CV patent is awarded. If this were also part of his plan he would then have a hell of a lot more to shout about at a conference.
All I know was his intent was to get the merger fully integrated, then get PPS above $30, where it will be more fairly traded and then to eventually find a partner for Libigel (no timeline given). .
